Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes

References

• Nimer SD. Myelodysplastic syndromes. Blood 2008;111: 4841–4851.
   PubMed Web of Science ®Google Scholar
• Lewis SM, Verwilghen RL. Dyserytropoiesis and dyserythropoietic anaemia. Br J Haematol 1972;23:1–4.
   PubMed Web of Science ®Google Scholar
• Catenacci DV, Shiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev 2005;19:301–319.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–3510.
   PubMed Web of Science ®Google Scholar
• Sanz GF, Sanz MA, Vallespí T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395–408.
   PubMed Web of Science ®Google Scholar
• Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006;91:1596–1604.
   PubMed Web of Science ®Google Scholar
• Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005;90: 1168–1178.
   PubMed Web of Science ®Google Scholar
• Sánchez-Castro J, Marco-Betés V, Gómez-Arbonés X, et al. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplatic syndrome. Leuk Res 2013;37:769–776.
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385–4395.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Schanz J, Tüchler H, Solé F, et al. A new, comprehensive cytogenetic scoring system for primary myelodysplastic syndromes and oligoblastic AML following MDS derived from an international database merge. J Clin Oncol 2012;30:820–829.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thépot S, Eclache V, et al. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011;25:1207–1209.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thépot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403–411.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429–2440.
   PubMed Web of Science ®Google Scholar
• Mallo M, Arenillas L, Espinet B, et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q–. Haematologica 2008;93;1001–1008.
   PubMed Web of Science ®Google Scholar
• Ademà V, Hernández JM, Abáigar M, et al. Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value? Leuk Res 2013;37:416–421.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN (2009): an international system for human cytogenetic nomenclature, Basel: S. Karger; 2009.
   Google Scholar
• Rigolin GM, Bigoni R, Milani R, et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 2001;15:1841–1847.
   PubMed Web of Science ®Google Scholar
• Cuneo A, Bigoni R, Cavazzini F, et al. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leucemia with normal karyotype. Leukemia 2002;16:1745–1751.
   PubMed Web of Science ®Google Scholar
• Soenen V, Preudhomme C, Roumiere C, et al. 17p deletion in acute myeloid leukemia and myelodysplastic syndrome. analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998;91;1008–1015.
   PubMed Web of Science ®Google Scholar
• Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer 2012;51: 1086–1092.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute at the National Institutes of Health. Childhood acute myeloid leukemia/other myeloid malignancies treatment (PDQ). Available from: www.cancer.gov/cancertopics/pdq/treatment/childAML/HealthProfessional
   Google Scholar
• Silveira CG, Oliveira FM, Valera ET, et al. New recurrent deletions in the PPAR gamma and TP53 genes are associated with childhood myelodysplastic syndrome. Leuk Res 2009;33: 19–27.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496–2506.
   PubMed Web of Science ®Google Scholar